Evidence map›Paper›PMID 38566168›Full record

ArticleHuman genomics2024

Profiling the role of m6A effectors in the regulation of pluripotent reprogramming.

Wenjun Wang, Lei Zhou, Hui Li, Tingge Sun, Xue Wen, Wei Li, Miguel A Esteban, Andrew R Hoffman, Ji-Fan Hu, Jiuwei Cui

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Human genomics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 46% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 2 countries.

Wenjun WangCancer Center, The First Hospital of Jilin University, Changchun, Jilin, 130021, China.
Lei ZhouCancer Center, The First Hospital of Jilin University, Changchun, Jilin, 130021, China.
Hui LiCancer Center, The First Hospital of Jilin University, Changchun, Jilin, 130021, China.
Tingge SunCancer Center, The First Hospital of Jilin University, Changchun, Jilin, 130021, China.
Xue WenCancer Center, The First Hospital of Jilin University, Changchun, Jilin, 130021, China.
Wei LiCancer Center, The First Hospital of Jilin University, Changchun, Jilin, 130021, China.
Miguel A EstebanGuangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, Guangdong, 510530, PR China.
Andrew R HoffmanVA Palo Alto Health Care System, Stanford University School of Medicine, Palo Alto, CA, 94304, USA.
Ji-Fan HuCancer Center, The First Hospital of Jilin University, Changchun, Jilin, 130021, China. jifan@stanford.edu.
Jiuwei CuiCancer Center, The First Hospital of Jilin University, Changchun, Jilin, 130021, China. cuijw@jlu.edu.cn.
First Hospital of Jilin University · CNJilin University · CNVA Palo Alto Health Care System · USChinese Academy of Sciences · CN

Funding

BLRD VA I01 BX002905VA BX002905
6 · The paper itself

Abstract

The N

Indexed as

Induced Pluripotent Stem CellsAnimalsCell DifferentiationCellular ReprogrammingEpigenesis, GeneticFibroblastsHumansMiceEpigeneticsIGF2BPsiPSCm6AReprogrammingStem cells

Identifiers

PMID38566168
PMCPMC10986062
OpenAlexW4393433588

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.